西妥昔单抗治疗老年k-RAS野生型转移性结直肠癌的临床分析

Abstract
Figure/Table
References (29)
Related Citation (15)

Download: PDF (567 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the efficacy of Cetuximab in the treatment of elderly k-RAS wild-type metastatic colorectal cancer (mCRC), and to provide a method for the treatment of this disease. Methods A total of 68 elderly patients with k-RAS wild-type mCRC admitted to NO. 904 Hospital of the Joint Logistics Support Force of the Liberation Army from October 2015 to October 2019 were selected as the research subjects. According to random number table method, they were divided into study group and control group, with 34 cases in each group. The control group received conventional chemotherapy, and the research group received Cetuximab in addition to the control group. The therapeutic effect was evaluated after 12 weeks of continuous treatment. The recent anti-tumor effect and the changes of tumor markers before and after treatment were compared between the two groups, and the safety of the two groups was statistically analyzed. Results The clinical control rate in the study group was higher than that in the control group, and the difference was statistically significant (P ＜ 0.05). Before treatment, there were no significant differences in serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 199 between the two groups (P ＞ 0.05). After treatment, CEA and CA199 in both groups were lower than those before treatment, and those in the study group were lower than those in the control group, with statistical significance (all P ＜ 0.05). There was no statistical significance in the incidence of acne-like rash, myelosuppression, liver function injury and digestive tract reaction between the two groups (P ＞ 0.05). Conclusion Cetuximab treatment for elderly patients with k-RAS wild-type mCRC can significantly enhance the anti-tumor efficacy, reduce the level of tumor markers and the patient are well tolerated.

Key words： Cetuximab Elderly K-RAS wild-type Metastatic colorectal cancer Curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TAN Qin1 REN Shun’an2 ZHOU Rengui1▲

Cite this article:

TAN Qin1 REN Shun’an2 ZHOU Rengui1▲. Clicinal analysis of Cetuximab in the treatment of elderly k-RAS wild-type metastatic colorectal cancer[J]. 中国医药导报, 2021, 18(23): 100-103.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I23/100

[1] Dekker E，Tanis PJ，Vleugels JLA，et al. Colorectal cancer [J]. Lancet，2019，394（207）：1467-1480.
[2] Wrobel P，Ahmed S. Current status of immunotherapy in metastatic colorectal cancer [J]. Int J Colorectal Dis，2019， 34（1）：13-25.
[3] 蒋华锋，沈毅，薛露，等.老年结直肠癌组织中miR-182表达及其与临床病理参数的关系[J].中国老年学杂志，2019，39（12）：2892-2894.
[4] Chakedis J，Schmidt CR. Surgical treatment of metastatic colorectal cancer [J]. Surg Oncol Clin N Am，2018，27（2）：377-399.
[5] 刘丹，粟文钊，吴忠良.双歧杆菌三联活菌联合XELOX化疗对大肠癌术后肠道菌群及免疫功能的影响[J].中国医药导报，2019，16（32）：119-122.
[6] 张音洁，王晰程，李健，等.三药联合方案治疗晚期转移性结直肠癌的疗效和安全性比较[J].中国肿瘤临床，2019， 46（4）：178-183.
[7] 周宇.肿瘤标志物基因表达与FOLFOX方案化疗后结直肠癌短中期预后的关系[J].中国临床药学杂志，2020，29（5）：32-36.
[8] Mazzarella L，Guida A，Curigliano G. Cetuximab for treating non-small cell lung cancer [J]. Expert Opin Biol Ther，2018，18（4）：483-493.
[9] 符洪犊，梁丽明.尼妥珠单抗与西妥昔单抗对食管癌放疗增敏作用的体外实验[J].现代消化及介入诊疗，2020， 25（5）：59-62.
[10] Concu R，Cordeiro MNDS. Cetuximab and the head and neck squamous cell cancer [J]. Curr Top Med Chem，2018，18（3）：192-198.
[11] 中华医学会消化内镜学分会，中国抗癌协会肿瘤内镜学专业委员会.中国早期结直肠癌筛查及内镜诊治指南（2014年，北京）[J].中华消化内镜杂志，2015，32（6）：341-360.
[12] Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline （version 1.1）[J]. Eur J Cancer，2009，45（2）：1-247.
[13] Boyd MR，Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen [J]. Drug Development Research，2010，34（2）：91-109.
[14] 刘志军，何忠良，陈国兴，等.西妥昔单抗联合化疗治疗中晚期食管癌的临床观察[J].中国医药导报，2019，16（23）：162-165.
[15] 潘建红，赵骏，韩景静，等.西妥昔单抗生物类似药临床比对研究设计的关键考虑[J].中国临床药理学杂志，2020， 36（10）：1381-1385
[16] 韩晶，门鹏，刘维，等.西妥昔单抗治疗转移性结直肠癌的快速卫生技术评估[J].中国新药杂志，2020，29（5）：582-588.
[17] 尹小五，夏秀梅，鲁斌.西妥昔单抗联合伊立替康治疗转移性结直肠癌的临床观察[J].中国现代医生，2019， 57（4）：28-30.
[18] 陈新，刘丹.西妥昔单抗体外增强人鼻咽癌细胞对紫杉醇化疗敏感性的实验研究[J].临床和实验医学杂志，2020，19（12）：1287-1291.
[19] 孙光源，史玉洁，李文贤，等.西妥昔单抗联合化疗治疗K-Ras野生型转移性结直肠癌的疗效及其影响因素分析[J].现代生物医学进展，2019，19（18）：3563-3567.
[20] 李琦俊，杨勇卫，王好平.CEA，CA19-9，CA50对老年结直肠癌术前临床分期的预判价值[J].老年医学与保健，2019，16（6）：668-669.
[21] 马雪芹，王学红，马臻棋，等.CEA，CA125，CA19-9对食管癌诊断的临床意义[J].实用癌症杂志，2019，34（5）：8-11.
[22] 黎杨杨，林裕锋，陈冬玲.结肠癌联合检测SAA、CRP和CEA的意义分析[J].中国医药科学，2020，10（16）：191-193.
[23] 卜晓敏，夏亮，李立文.血清淀粉样蛋白A联合肿瘤标志物检测在老年肺癌诊疗中的应用[J].中国医药导报，2020，17（31）：162-165，169.
[24] 郁肖夫，郑晓.糖类抗原CA125 CA199 CA724癌胚抗原对大肠癌的诊断价值[J].中国药物与临床，2019，19（3）：53-55.
[25] 张鑫东，葛晓蕾，刘省存，等.血清CA199和CEA对结直肠癌转移和预后预测的价值[J].中华疾病控制杂志，2018，22（1）：57-61.
[26] 刘继琐，钱广明，邢芳.西妥昔单抗联合化疗治疗三阴性乳腺癌的效果观察[J].解放军预防医学杂志，2019， 37（6）：112-113.
[27] Kopetz S，Grothey A，Yaeger R，et al. Encorafenib，binimetinib，and cetuximab in BRAF v600E-mutated colorectal cancer [J]. N Engl J Med，2019，381（17）：1632-1643.
[28] 周永春，林艳苹，李权，等.云南省肺癌患者表皮生长因子受体基因突变的临床特征分析[J].中华肿瘤杂志，2020， 42（9）：729-734.
[29] Kong Y，Hong L，Xu X. Potentially resectable mCRC-treated with cetuximab combined with chemotherapy [J]. J Coll Physicians Surg Pak，2020，30（11）：1206-1212.